Decision making and the treatment of localized prostate cancer today

This month’s issue of Urologic Oncology contains a series of six articles that may be of particular interest to prostate cancer support group leaders and other prostate cancer educators. … READ MORE …

Comparative effectiveness, radiation therapy, and prostate cancer treatment

There is an interesting article about assessment of the comparative effectiveness of different types of radiation therapy in the management of prostate cancer in the December 2013 issue of Oncology. … READ MORE …

STAMPEDE: an important trial in the management of advanced prostate cancer

Most of the time, when we talk about clinical trials of drugs (or other treatments) for prostate cancer, we are talking about trials in which new treatment X is compared to standard (current) treatment Y or, if there is no standard, new treatment Z is compared to a placebo (a benign, “dummy” substitute). … READ MORE …

Relative value of 3D-CRT, IMRT, and PBRT in prostate cancer published in JAMA

In February we reported on a presentation by Sheets et al. at the Genitourinary Cancer Symposium. The presentation addressed the comparative effectiveness and safety of  3D conformal, intensity-modulated, and proton beam forms of radiation therapy (3D-CRT, IMRT, and PBRT, respectively). … READ MORE …

Two interesting articles on Medscape recently

A couple of recent articles on the Medscape web site deal with aspects of the effectiveness and safety of robot-assisted laparoscopic prostatectomy (RALP) and various types of radiation therapy in the first-line treatment of prostate cancer. … READ MORE …

Relative 10-year survival after surgery, EBRT, or brachytherapy in the PSA era

A new study on relative rates of survival at 10 years, just published on line, is probably going to get differing reactions from patients and from physicians depending on their individual points of view. … READ MORE …

Is low-dose brachytherapy really “better” than other treatment options (redux)?

An article just published by Grimm et al. in a supplement to BJU International argues (quite persuasively) that low-dose brachytherapy is the best form of treatment for men with low-risk prostate cancer. … READ MORE …